Pacira BioSciences, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +1.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.27 | $0.44 | +63.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $0.33 | $0.34 | +3.0% | Beat | |
| Q4 FY25 | $0.60 | $0.32 | -46.7% | Miss | Q4 FY25 call |
| Q3 FY25 | $0.42 | $0.46 | +9.5% | Beat | |
| Q2 FY25 | $0.49 | $0.47 | -4.1% | Miss | |
| Q1 FY25 | $0.37 | $0.39 | +5.4% | Beat | |
| Q4 FY24 | $0.62 | $0.71 | +14.5% | Beat | |
| Q3 FY24 | $0.50 | $0.53 | +6.0% | Beat | |
| Q2 FY24 | $0.53 | $0.64 | +20.8% | Beat | |
| Q1 FY24 | $0.46 | $0.42 | -8.7% | Miss | |
| Q4 FY23 | $0.71 | $0.71 | +0.0% | Beat | |
| Q3 FY23 | $0.65 | $0.52 | -20.0% | Miss |
Back to PCRX overview · PCRX holders · PCRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.